1 rich Libsyn https://www.libsyn.com 90 600 The TRANQUILITY trial was designed to evaluate whether pacibekitug can reduce interleukin-6 (IL-6)-driven inflammation, a key inflammatory pathway increasingly linked to cardiovascular risk. Treatment with pacibekitug demonstrated favorable effects on inflammatory and cardiovascular risk biomarkers, supporting IL-6 inhibition as a potential therapeutic strategy for reducing residual inflammatory risk. These findings further strengthen the evidence implicating IL-6 as an important mediator of cardiovascular disease.&amp;nbsp; In this episode, Dipti Itchhaporia MD, MACC and Deepak L. Bhatt, MD, MPH, MBA, FACC discuss TRANQUILITY: Efficacy of monthly and quarterly dosing of pacibekitug (IL-6 ligand mAb) targeting inflammation in CKD with high cardiovascular risk. ACCEL Lite: Featured ACCEL Interviews on Exciting CV Research http://www.acc.org <iframe title="Libsyn Player" style="border: none" src="//html5-player.libsyn.com/embed/episode/id/43353574/height/90/theme/custom/thumbnail/yes/direction/forward/render-playlist/no/custom-color/88AA3C/" height="90" width="600" scrolling="no" allowfullscreen webkitallowfullscreen mozallowfullscreen oallowfullscreen msallowfullscreen></iframe> https://assets.libsyn.com/secure/content/207819279